News more

  • On the Agenda: Law and the Environment, Financing Growth, and Non-Competes—Foley Hoag Launches Three New Blogs  [Read More]
  • Foley Hoag Congratulates Inaugural Class of New England Clean Energy Council's Fellowship Program  [Read More]
  • Foley Hoag Successfully Represents Republic of Georgia: Receives Favorable Ruling from ICJ  [Read More]
  • Foley Hoag Partner Dean Richlin Admitted to American College of Trial Lawyers  [Read More]
  • Foley Hoag Economic Crisis Team
    Now’s the Time:
    Foley Hoag Forms Economic Crisis Team  [Read More]

Publications more

Events more

November 19, 2008 Video Game Gold: the Prosperous Gaming Industry in Massachusetts [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
November 21, 2008 Information and Communications Technology at Greenbuild: The Springboard for Innovation and Execution [Read More] UK Trade and Investment
Cambridge, MA
December 2, 2008 Tech Talk Tuesday {T3}: The War for Clean Tech Talent [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
December 3, 2008 TCN Breakfast Roundtable" Angel Group & Venture Capital Term Sheets [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
December 10, 2008 Understanding the New Data Security Law [Read More] Foley Hoag LLP (Boston Office)
Boston, MA

Client Successes

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • HyperBranch Medical Technology, Inc.
    For our client HyperBranch Medical Technology, Inc., a leader in the field of polymeric medical sealants, we assisted with the intellectual property portfolio strategy in connection with obtaining CE Mark designation for the company’s OcuSeal product. OcuSeal is a liquid ocular bandage used to stabilize ocular wounds following surgical or non-surgical trauma. CE Marking denotes that a product complies with all requirements of European health, safety, and environmental product legislation, and is an important step in bringing products to market overseas. HyperBranch began its research in 2004 with the objective to develop strong enough polymer sealants to ultimately replace sutures that would be easy to use, and would not interfere with natural healing. The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development. Read more about HyperBranch Medical Technology here. [Read More]